ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 190 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,700 | -66.4% | 13,156 | -58.6% | 0.01% | -64.3% |
| Q2 2023 | $213,405 | -31.8% | 31,804 | -10.3% | 0.01% | -26.3% |
| Q1 2023 | $313,059 | +80.7% | 35,454 | +56.3% | 0.02% | +111.1% |
| Q4 2022 | $173,260 | -76.3% | 22,678 | -77.9% | 0.01% | -65.4% |
| Q3 2022 | $732,000 | -3.9% | 102,816 | +9.1% | 0.03% | +18.2% |
| Q2 2022 | $762,000 | -62.2% | 94,225 | -35.1% | 0.02% | -62.1% |
| Q1 2022 | $2,015,000 | +811.8% | 145,182 | +2137.4% | 0.06% | +866.7% |
| Q3 2021 | $221,000 | -31.2% | 6,489 | -17.3% | 0.01% | -40.0% |
| Q2 2021 | $321,000 | -80.5% | 7,850 | -80.8% | 0.01% | -76.7% |
| Q1 2021 | $1,646,000 | +445.0% | 40,893 | +699.9% | 0.04% | +437.5% |
| Q4 2020 | $302,000 | +357.6% | 5,112 | +274.0% | 0.01% | +166.7% |
| Q3 2020 | $66,000 | +1550.0% | 1,367 | +855.9% | 0.00% | – |
| Q3 2019 | $4,000 | – | 143 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |